Shares of United Therapeutics Corp (Symbol: UTHR) have exceeded the average analyst 12-month target price of $368.50, currently trading at $369.96 per share. There are 12 analysts contributing to UTHR’s target, with predictions ranging from a low of $240.00 to a high of $575.00, showcasing a standard deviation of $82.884.
The recent analyst ratings indicate 9 strong buy ratings, 4 hold ratings, and 1 sell rating. The average analyst rating is 1.79, on a scale where 1 represents a strong buy and 5 indicates a strong sell. This data was sourced from Zacks Investment Research via Quandl.com.
